アラバマ州における卵巣がんの臨床試験
アラバマ州内の拠点で、卵巣がんに関する27件の研究が参加者を募集しています。
アラバマ州内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Alabama at Birmingham Cancer Center, Birmingham
- University of South Alabama Mitchell Cancer Institute, Mobile
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Dothan Hematology & Oncology, Dothan
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07189871A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0170-USA Mitchell Cancer Institute, Mobile
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT05128825A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793, Birmingham
- Usa Mitchell Cancer Institute /ID# 276022, Mobile
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT06890338Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- University of Alabama_6th Ave, Birmingham
被験者募集中第1/2相
18歳以上 · 女性 · 2026/09/25更新 · NCT03564340A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Alabama at Birmingham, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213804A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- University of Alabama - Birmingham ( Site 0058), Birmingham
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Usa Health Mitchell Cancer Institute, Mobile
被験者募集中第2相
18歳〜99歳 · 女性 · 2026/09/15更新 · NCT07023627FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- The University of Alabama, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06303505Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- The University of Alabama at Birmingham, Birmingham
被験者募集中第2相
18歳以上 · 女性 · 2026/09/14更新 · NCT06787612ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Alabama at Birmingham, Birmingham
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- University of Alabama at Birmingham ( Site 0006), Birmingham
被験者募集中第3相
18歳以上 · 女性 · 2026/09/03更新 · NCT06824467Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- The University of South Alabama, Mitchell Cancer Institute, Mobile
被験者募集中第3相
18歳以上 · 女性 · 2026/08/26更新 · NCT05281471Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Alabama, Birmingham
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119Study of NTB-928 in R/R OC
- The University of Alabama, Birmingham
被験者募集中第1相
18歳以上 · 女性 · 2026/08/20更新 · NCT07690189A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
被験者募集中
35歳〜50歳 · 女性 · 2026/08/07更新 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/07更新 · NCT06580314A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Alabama at Birmingham, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
- University of Alabama at Birmingham, Birmingham
被験者募集中観察研究健康なボランティア歓迎
18歳〜99歳 · 女性 · 2026/07/29更新 · NCT03538665Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 004, Birmingham
被験者募集中第2相
18歳以上 · 女性 · 2026/07/16更新 · NCT06906341Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Alabama at Birmingham Womens & Infants Center, Birmingham
被験者募集中第2相
18歳以上 · 女性 · 2026/07/14更新 · NCT04606914Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
被験者募集中第2相
18歳以上 · 女性 · 2026/06/29更新 · NCT05952453Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
被験者募集中
18歳以上 · 全性別 · 2026/04/30更新 · NCT05297734SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。